Clinical trial results found that a new antibiotic candidate could shorten TB treatment from the standard 6 months to 8 weeks ...

Researchers have unveiled new AI tools, from smartphone cough analysis to child-friendly screening systems, which could ...

The bacteria Mycobacterium tuberculosis, which causes the world's most infectious disease Tuberculosis (TB), can survive antibiotic treatment and live longer by changing their outer fat coating, ...

African scientists have developed a nanoscale drug delivery system to treat pericarditis, a drug-resistant and lethal ...

An individual within the Aegis Living retirement community in Issaquah was diagnosed with active tuberculosis on Monday.

An international team of investigators today announced promising data from a trial of a novel antibiotic that could ...

New clinical trial results presented by TB Alliance at the Union World Conference on Lung Health show that the novel ...

This is a prospective observational study that will enroll individuals with suspected pulmonary TB and follow those with culture-confirmed, rifamycin-sensitive TB for 18 months, from the initiation of ...

An expert panel calls the requirement for tuberculosis testing before prescribing IL-17 and IL-23 biologics for psoriasis an ...

A clinical drug trial conducted in five Sub-Sahara African countries shows that a shortened (four month) treatment for tuberculosis (TB) is well tolerated and may work well in subsets of TB patients, ...

Treatment of latent tuberculosis is set to transform after a pair of studies revealed that a shorter treatment was safer and more effective in children and adults compared to the current standard.

The Food and Drug Administration approved a new tuberculosis medicine that shortens and improves treatment for the hardest-to-treat cases, a worsening problem in many poor countries. It's the first TB ...